DMD: What Are the Measures That Matter? DMD: What Are the Measures That Matter?
Watch this exciting on-demand symposium, presented by Dr Tina Duong and Prof Laurent Servais, to learn more about functional assessment tools used in Duchenne muscular dystrophy, as well as when and how we should use these tools.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Reflex Amends Ruby Graphite Project Deal
Freedom Battery Metals, Inc. (TSE:RFLX) has released an update. Reflex Advanced Materials Corp. has amended its agreement regarding the Ruby Graphi...#tse #rflx (Source: Reuters: Health)
Source: Reuters: Health - April 22, 2024 Category: Consumer Health News Source Type: news
Nigeria: Why You Should Ditch the Booze When You're Pregnant!
[Vanguard] Imagine when your pregnancy is scanned for the first time so you could see your precious baby growing in the womb, suddenly its whole body gives a shudder and the foetus appears to jump. Such a movement is known as the startle reflex; and the scan described above are from photographs from scans that were taken by Peter Hepper, a professor of psychology at Queens University, Belfast, an expert on the effects of alcohol on unborn babies. (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - April 22, 2024 Category: OBGYN Tags: Health and Medicine Nigeria Nutrition Pregnancy and Childbirth West Africa Source Type: news
Utility of intraoral scanner imaging for dental plaque detection
Conclusion: When employing IOS with dental plaque staining, the impact of color was minimal, suggesting that the traditional red stain remains suitable for plaque detection. IOS images appeared relatively blurred and enlarged relative to the true state of the teeth, due to inferior sharpness compared to camera images. (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 17, 2024 Category: Dentistry Source Type: news
Roche ’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III...
Source: Roche Media News - April 17, 2024 Category: Pharmaceuticals Source Type: news
Possible Pulmonary Benefit With Viltolarsen for Duchenne Muscular Dystrophy
(MedPage Today) -- DENVER -- Viltolarsen (Viltepso) was well tolerated by boys and men with Duchenne muscular dystrophy (DMD), with no new safety signals, according to results from the open-label, phase II Galactic53 trial.
The results also... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 16, 2024 Category: Neurology Source Type: news
Jack was given pioneering drink to beat muscle wasting disease and can still stand. His best friend Eli didn't get the drug and now he is permanently in a wheelchair. Their contrasting stories prove new treatment works, so why is NHS rollout at risk?
Eli Crossley and Jack Johnson (pictured) both have Duchenne muscular dystrophy (DMD) -progressive muscle-wasting disease. (Source: the Mail online | Health)
Source: the Mail online | Health - April 6, 2024 Category: Consumer Health News Source Type: news
Calls grow for RFK Jr. to drop out after remarks sympathetic to Jan. 6 rioters
MoveOn Executive Director Rahna Epting joins MSNBC’s Ali Velshi to discuss why independent presidential candidate Robert Kennedy Jr. should end his bid for the White House.#rahnaepting #msnbc #alivelshi #robertkennedyjr (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
Givinostat Slows Duchenne Muscular Dystrophy Decline
(MedPage Today) -- Givinostat (Duvyzat) slowed physical decline as measured by stair climbing speed for a subset of boys with Duchenne muscular dystrophy (DMD), according to the phase III trial that supported the drug's recent approval for this... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 5, 2024 Category: Neurology Source Type: news
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024. Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days Fireside Chat: Wednesday,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 27, 2024 Category: Pharmaceuticals Tags: FVT Source Type: news
COVID-Cautious Americans Feel Abandoned
For all of 2020, Alex, a 28-year-old living in New York, followed the U.S. Centers for Disease Control and Prevention’s (CDC) COVID-19 guidance “religiously.” Then, in 2021, something began to shift. That spring, the CDC said it was okay for vaccinated people to ditch their masks in most places. But people were clearly still getting sick—including Alex, who got COVID-19 for the first time in late 2021 and later developed Long COVID symptoms.
[time-brightcove not-tgx=”true”]
“There was this reckoning moment where it was like, ‘Maybe the CDC is not being totally honest with...
Source: TIME: Health - March 27, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Living With Muscular Dystrophy at 50 Makes Death My Shadow Partner
I am an Aries through and through—bold, ambitious, fiery, and confident. Today, March 27, marks my 50th year on this planet, something I could never have imagined. I was diagnosed with an undetermined type of muscular dystrophy as a young child, and doctors told my parents I wouldn’t live to become an adult. My immigrant parents cried when they heard the news. Even though this news was devastating, they never treated me like a fragile egg about to break. In fact, as the first born child of three girls, I had a lot of responsibilities and expectations which only reinforced my Aries tendencies.
[time-bright...
Source: TIME: Health - March 27, 2024 Category: Consumer Health News Authors: Alice Wong Tags: Uncategorized freelance Source Type: news
FDA Approves Oral Duvyzat for Duchenne Muscular Dystrophy
MONDAY, March 25, 2024 -- The U.S. Food and Drug Administration has approved Duvyzat (givinostat) as an oral medication for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.Duvyzat is a histone deacetylase... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2024 Category: Pharmaceuticals Source Type: news
AI Chatbots for Mental Health Have Arrived, Despite Limited Evidence They Work
(MedPage Today) -- Download the mental health chatbot Earkick and you're greeted by a bandana-wearing panda who could easily fit into a kids' cartoon.
Start talking or typing about anxiety and the app generates the kind of comforting, sympathetic... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 25, 2024 Category: Psychiatry Source Type: news
FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
The U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle. (Source: World Pharma News)
Source: World Pharma News - March 25, 2024 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
